Pfizer’s $100B Peak Revenue Slumps as Blockbuster Patents Expire
Pfizer’s revenue peaked at $100 billion driven by COVID treatments but has since declined markedly as demand wanes. Imminent patent expirations on major blockbusters threaten to erode future revenues and margins.
1. Revenue Peak and Post-Pandemic Decline
Pfizer’s revenue surged past $100 billion during the COVID-19 pandemic, driven by antiviral treatments and vaccine sales. Since reaching that peak, demand for these products has fallen sharply, leading to a notable downturn in quarterly top-line performance.
2. Blockbuster Patent Expirations Threaten Future Earnings
Several of Pfizer’s key drugs are approaching the end of their patent protection, opening the door for generic competition. Loss of exclusivity on these blockbusters could significantly reduce pricing power and compress margins in the coming years.
Related News
Z
Zillow Mortgage Rates Climb: 30-Year Fixed Hits 6.55%, 5/1 ARM at 6.80%
Z•
NVDA
Hedge Funds Back Nvidia-Powered AI Data Centers as Shares Fall 1.3% After $80B Buyback
NVDA•
VZLA
Vizsla Silver Taps 20-Year Veteran Hernandez as VP Exploration, Promotes Velador
VZLA•
BCS
Samsung Electronics Agrees 40 Trillion Won Bonus Package for Chip Workers
BCS•
MA
Chargebacks911 Partners with acceptcards to Reduce Chargebacks as UK Card Use Tops £1 Trn
MA•
Sources
FPF